FIDELITY汇总分析:finerenone在eGFR急性变化患者中的疗效与安全性
FIDELITY汇总分析纳入12,798例CKD合并2型糖尿病患者,按起始治疗后1个月eGFR变化分组,评估finerenone对复合心血管和肾脏结局的影响。结果显示finerenone的获益不受急性eGFR变化影响,各eGFR变化亚组中心血管和肾脏获益相似。
要点
- finerenone起始后1个月eGFR变化不影响其心血管和肾脏获益。
- 急性eGFR下降与基线尿白蛋白肌酐比、eGFR、收缩压及利尿剂/β受体阻滞剂使用相关。
- finerenone总体显著降低复合心血管和肾脏结局风险。
核心结论
- finerenone的心血管和肾脏获益不受起始治疗后急性eGFR变化的影响。
研究设计与样本
- FIDELITY为两项临床试验的汇总个体水平分析,共纳入12,798例CKD(eGFR≥25 ml/min/1.73 m2)合并2型糖尿病且已优化RAS阻断的患者。
主要发现
- 治疗1个月后,25.1%患者eGFR下降>10%,31.2%下降>0-10%,26.8%升高0-10%,16.8%升高>10%。
- finerenone总体显著降低复合心血管和肾脏结局风险。
- 按eGFR变化亚组(下降>10%、下降>0-10%、升高0-10%、升高>10%)分析,复合心血管结局HR(95%CI)分别为0.74(0.61-0.90)、0.87(0.73-1.04)、1.06(0.87-1.28)、0.78(0.61-0.99),P交互=0.048。
- 肾脏结局HR(95%CI)分别为0.67(0.53-0.85)、0.78(0.61-1.01)、0.56(0.40-0.77)、0.75(0.50-1.14),P交互=0.23。
- 将急性eGFR变化作为连续变量建模时,finerenone降低心血管和肾脏结局风险不受其影响(P交互分别为0.58和0.36)。
临床怎么用
- 临床中finerenone起始后出现急性eGFR变化时,不应因此质疑其长期心血管和肾脏获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The efficacy and safety of finerenone (a nonsteroidal mineralocorticoid receptor antagonist) versus placebo were assessed according to different changes in estimated glomerular filtration rate (eGFR) using data from FIDELITY, a pooled individual-level analysis of two clinical trials. METHODS: Patients had chronic kidney disease (eGFR of 25 ml/min/1.73 m2 or greater) and type 2 diabetes with optimized renin-angiotensin system blockade. Risk of composite cardiovascular and composite kidney outcomes was analyzed by baseline eGFR change at month one in the total population and by treatment group. RESULTS: Of 12,798 patients, 25.1% had a >10% eGFR decline, 31.2% had a >0-10% decline, 26.8% had a 0-10% increase, and 16.8% had a >10% increase after one month of treatment. Factors associated with acute eGFR decline included higher baseline urine albumin-to-creatinine ratio, eGFR, systolic blood pressure, diuretic or beta-blocker use, and finerenone use. Finerenone significantly reduced composite cardiovascular and kidney outcomes overall and had similar beneficial effect across eGFR subgroups of >10% decline, >0-10% decline, 0-10% increase, and >10% increase for composite cardiovascular (hazard ratio [95% Confidence Interval] of 0.74 [0.61-0.90], 0.87 [0.73-1.04], 1.06 [0.87-1.28], and 0.78 [0.61-0.99], respectively) and kidney outcomes (0.67 [0.53-0.85], 0.78 [0.61-1.01], 0.56 [0.40-0.77], and 0.75 [0.50-1.14], respectively) (P interaction 0.048 and 0.23, respectively). When modeled as a continuous variable, finerenone reduced the risk of cardiovascular and kidney outcomes, irrespective of acute eGFR change (P interaction 0.58 and 0.36, respectively). CONCLUSIONS: The cardiovascular and kidney benefits of finerenone were not modified by an acute eGFR change after drug initiation.
引用
- Navaneethan SD, Anker SD, Filippatos G, et al. Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis. Kidney Int. 2025. PMID: 40268166. doi:10.1016/j.kint.2025.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。